# CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

> **NCT04154709** · PHASE1 · UNKNOWN · sponsor: **Kai Lin Xu; Jun Nian Zheng** · enrollment: 15 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CTA101

## Key facts

- **NCT ID:** NCT04154709
- **Lead sponsor:** Kai Lin Xu; Jun Nian Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-10
- **Primary completion:** 2021-11
- **Final completion:** 2022-06
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2020-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04154709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04154709, "CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04154709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*